Diseases Cached

Human Immunodeficiency Virus (HIV): Symptoms, Treatments, Medications and Prevention

by ·

Human Immunodeficiency Virus (HIV) is a chronic, potentially life-threatening virus that attacks the body’s immune system, specifically the CD4 cells (also called T cells), which are essential for immune function. Without proper treatment, HIV can progress to Acquired Immunodeficiency Syndrome (AIDS), a severe immune deficiency that leaves individuals vulnerable to opportunistic infections and certain cancers. Although HIV is a global health challenge, advances in medicine have transformed it into a manageable condition with early diagnosis and lifelong treatment.

What is HIV?

HIV is a retrovirus that primarily infects the immune system, weakening the body’s ability to fight infections and disease. It is transmitted through contact with certain body fluids, including blood, semen, vaginal fluids, rectal fluids, and breast milk. HIV progresses through several stages, eventually leading to AIDS if left untreated. However, with modern antiretroviral therapy (ART), people with HIV can live long and healthy lives without progressing to AIDS.

Stages of HIV Infection

  1. Acute HIV Infection: This is the first stage of HIV, occurring within 2 to 4 weeks after infection. During this phase, the virus multiplies rapidly, and people may experience flu-like symptoms. This is also when HIV is most contagious, as the viral load is extremely high.
  2. Chronic HIV Infection (Clinical Latency Stage): Also known as the asymptomatic or latent phase, this stage can last for many years. During this time, the virus continues to multiply at low levels, and individuals may not show any symptoms. If left untreated, this stage can last up to 10 years or more.
  3. AIDS (Acquired Immunodeficiency Syndrome): AIDS is the most advanced stage of HIV infection. It occurs when the CD4 count drops below 200 cells/mm³, and the immune system is severely compromised. At this stage, individuals are vulnerable to opportunistic infections and certain cancers. Without treatment, AIDS typically leads to death within three years.

Who is at Risk of HIV?

HIV can affect anyone regardless of age, gender, or sexual orientation, but certain populations are at a higher risk of contracting the virus due to behaviors, social factors, and geographic location. Understanding who is at higher risk helps to target prevention and treatment efforts.

High-Risk Populations for HIV

  1. Men Who Have Sex with Men (MSM): MSM continue to be disproportionately affected by HIV due to biological and social factors. Unprotected anal sex carries a higher risk of HIV transmission than vaginal sex because the rectal lining is more susceptible to tears, which can allow the virus to enter the bloodstream.
  2. People Who Inject Drugs (PWID): Sharing needles or other drug paraphernalia puts individuals at high risk for HIV infection, as the virus can be transmitted through contaminated blood on the equipment.
  3. Heterosexual Individuals in High-Prevalence Areas: In regions where HIV is highly endemic, particularly in sub-Saharan Africa, heterosexual transmission is the primary mode of HIV infection. Women are disproportionately affected in these areas, often due to gender inequalities that limit their ability to negotiate safer sex practices.
  4. Sex Workers: Individuals who engage in sex work are at a higher risk of contracting HIV due to frequent unprotected sex, multiple partners, and social stigma, which can hinder access to prevention services and healthcare.
  5. Transgender People: Transgender individuals, particularly transgender women, face a heightened risk of HIV due to multiple factors, including high rates of unprotected sex, discrimination in healthcare, and higher rates of poverty and substance use.
  6. Healthcare Workers: Healthcare workers are at risk of HIV infection through accidental needlestick injuries or exposure to contaminated blood and body fluids. However, this risk can be minimized through proper use of personal protective equipment (PPE) and post-exposure prophylaxis (PEP).
  7. Infants Born to HIV-Positive Mothers: HIV can be transmitted from mother to child during pregnancy, childbirth, or breastfeeding. However, with antiretroviral treatment during pregnancy and the avoidance of breastfeeding, the risk of transmission can be significantly reduced.

Symptoms of HIV

The symptoms of HIV vary depending on the stage of infection. Many people with HIV do not show symptoms for years, but the virus continues to damage their immune system. Early diagnosis is key to preventing progression to AIDS.

Symptoms of Acute HIV Infection

The acute phase of HIV, often referred to as primary HIV infection or acute retroviral syndrome (ARS), occurs within 2 to 4 weeks after the virus enters the body. During this time, the viral load is very high, and symptoms resemble those of the flu or other viral illnesses. Common symptoms include:

  1. Fever: A persistent fever is one of the most common symptoms during acute HIV infection.
  2. Fatigue: Many people experience extreme tiredness and a general feeling of malaise.
  3. Swollen Lymph Nodes: Lymph nodes, especially those in the neck and armpits, may become enlarged as the body tries to fight off the infection.
  4. Sore Throat: A painful, swollen throat is common during this stage.
  5. Rash: A rash can develop, usually on the upper body, and may be itchy or mildly painful.
  6. Muscle and Joint Aches: Body aches, including muscle and joint pain, are frequent symptoms.
  7. Night Sweats: Profuse sweating during sleep, often drenching the bed sheets, may occur.
  8. Headache: Some individuals may experience severe headaches.

Symptoms of Chronic HIV Infection

After the initial acute phase, HIV enters the chronic stage, during which symptoms may be mild or absent. However, the virus continues to replicate at lower levels, gradually weakening the immune system. Over time, individuals may develop:

  1. Persistent Swelling of the Lymph Nodes: Swollen lymph nodes may persist even in the absence of other symptoms.
  2. Unexplained Weight Loss: Gradual weight loss can occur without a clear reason.
  3. Recurrent Fever: Low-grade fevers may occur intermittently.
  4. Frequent Infections: Because the immune system is weakened, individuals may experience more frequent bacterial, viral, and fungal infections.

Symptoms of AIDS

If HIV is left untreated and progresses to AIDS, the immune system becomes severely compromised. At this stage, individuals are highly susceptible to opportunistic infections and cancers, which are typically rare in people with healthy immune systems. Symptoms of AIDS include:

  1. Severe Weight Loss: Known as wasting syndrome, this involves extreme, unexplained weight loss.
  2. Chronic Diarrhea: Persistent diarrhea that lasts more than a few days is common.
  3. Night Sweats: Profuse, unexplained night sweats occur frequently.
  4. Severe Infections: Opportunistic infections, such as tuberculosis, pneumonia, and fungal infections, become common and can be life-threatening.
  5. Kaposi’s Sarcoma: This type of cancer causes purple or red lesions on the skin and other organs.
  6. Neurological Symptoms: AIDS can lead to neurological issues, including confusion, memory loss, and motor impairments due to infections like toxoplasmosis or HIV-related encephalopathy.

Diagnosis of HIV

Early diagnosis of HIV is crucial for starting treatment as soon as possible to prevent the virus from progressing and to reduce the risk of transmission to others. There are several diagnostic tools and tests used to detect HIV infection.

Initial Screening Tests for HIV

  1. HIV Antibody Test: This is the most common screening test for HIV. It detects antibodies produced by the immune system in response to HIV. Most people develop detectable antibodies within 3 to 12 weeks after infection. Modern versions of this test can detect antibodies sooner than older methods.
  2. HIV Antigen/Antibody Test: This test detects both HIV antibodies and antigens (specifically the p24 antigen), which appear earlier in the infection process. This test can diagnose HIV infection earlier than antibody-only tests.
  3. Rapid HIV Test: Rapid tests can provide results in 20 to 30 minutes and are often used in community health settings. They can be conducted using blood or oral fluid samples.
  4. Home Testing Kits: FDA-approved home testing kits allow individuals to collect samples (either blood from a fingerstick or oral fluid) and send them to a lab or receive results at home.

Confirmatory Tests for HIV

  1. Western Blot Test: Traditionally, the Western blot test has been used to confirm a positive HIV diagnosis after an initial screening test. However, its use has declined in favor of newer methods.
  2. Nucleic Acid Test (NAT): NATs detect HIV RNA (the genetic material of the virus) in the blood and are typically used to confirm a diagnosis after a positive screening test. NATs can detect HIV as early as 10 to 33 days after exposure.
  3. HIV Viral Load Test: This test measures the amount of HIV in the blood and is often used after diagnosis to monitor the effectiveness of treatment. A higher viral load indicates more active replication of the virus.

Monitoring HIV After Diagnosis

  1. CD4 Count: This test measures the number of CD4 cells in a sample of blood. A normal CD4 count ranges from 500 to 1,600 cells per cubic millimeter. A declining CD4 count indicates a weakening immune system.
  2. HIV Viral Load: This test is repeated regularly to monitor the effectiveness of antiretroviral therapy (ART). The goal of treatment is to reduce the viral load to undetectable levels, meaning the virus is present at such low levels that it cannot be detected by the test or transmitted to others.

Treatment of HIV

Although there is no cure for HIV, the condition can be effectively managed with antiretroviral therapy (ART). ART suppresses the replication of the virus, allowing the immune system to recover and preventing the progression of HIV to AIDS.

Goals of HIV Treatment

  1. Suppress Viral Load: The primary goal of ART is to reduce the viral load to undetectable levels. When the viral load is undetectable, HIV cannot be transmitted to others, and the immune system is protected from further damage.
  2. Increase CD4 Cell Count: By suppressing the virus, ART allows the CD4 count to recover and helps maintain a healthy immune system.
  3. Prevent Opportunistic Infections: ART helps reduce the risk of opportunistic infections and other complications associated with a weakened immune system.
  4. Improve Quality of Life: With effective treatment, individuals with HIV can lead long, healthy lives and have a normal life expectancy.

Antiretroviral Therapy (ART)

ART involves the use of a combination of HIV medications from different classes to attack the virus at different stages of its life cycle. This combination therapy is essential to prevent the virus from developing resistance to a single drug. ART is typically a lifelong treatment, and adherence to the medication regimen is critical for its success.

  1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs): These drugs block reverse transcriptase, an enzyme HIV uses to convert its RNA into DNA. By doing so, NRTIs prevent the virus from replicating. Common NRTIs include:
    • Zidovudine (Retrovir)
    • Tenofovir (Viread)
    • Emtricitabine (Emtriva)
    • Lamivudine (Epivir)
  2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): NNRTIs also inhibit reverse transcriptase, but they do so by binding directly to the enzyme, preventing it from functioning. Examples include:
    • Efavirenz (Sustiva)
    • Nevirapine (Viramune)
    • Rilpivirine (Edurant)
  3. Protease Inhibitors (PIs): PIs block the protease enzyme, which HIV needs to cut long chains of viral proteins into smaller pieces that are essential for building new virus particles. Common PIs include:
    • Atazanavir (Reyataz)
    • Darunavir (Prezista)
    • Ritonavir (Norvir)
  4. Integrase Strand Transfer Inhibitors (INSTIs): These drugs block HIV integrase, an enzyme that HIV uses to insert its DNA into the host cell’s DNA. By inhibiting integrase, these drugs prevent the virus from replicating. Common INSTIs include:
    • Dolutegravir (Tivicay)
    • Raltegravir (Isentress)
    • Bictegravir (found in Biktarvy)
  5. Entry Inhibitors: These drugs prevent HIV from entering human immune cells. There are two types of entry inhibitors:
    • CCR5 Antagonists: These block the CCR5 co-receptor on the surface of CD4 cells, preventing the virus from entering the cell. Example: Maraviroc (Selzentry).
    • Fusion Inhibitors: These drugs prevent the fusion of the virus with the CD4 cell membrane. Example: Enfuvirtide (Fuzeon).
  6. Pharmacokinetic Enhancers (Boosters): These drugs boost the effectiveness of other HIV medications, particularly protease inhibitors. Example: Cobicistat (Tybost).

Treatment Adherence

Adherence to ART is essential for achieving viral suppression and maintaining a healthy immune system. Missing doses or stopping treatment can lead to drug resistance, making the virus harder to treat. Patients are encouraged to maintain regular contact with their healthcare providers to manage side effects, monitor treatment progress, and ensure adherence.

Most Common Medications for HIV

HIV treatment typically involves a combination of medications to effectively suppress the virus and prevent drug resistance. Here are some of the most commonly used medications for treating HIV:

Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

  1. Tenofovir Disoproxil Fumarate (TDF): TDF is a key component of many first-line ART regimens. It is highly effective at suppressing HIV replication but can cause side effects such as kidney toxicity and bone loss in some patients.
  2. Emtricitabine (FTC): Often used in combination with TDF, Emtricitabine is a well-tolerated NRTI with a low side effect profile. It is commonly found in combination pills such as Truvada and Descovy.
  3. Lamivudine (3TC): Lamivudine is another widely used NRTI, especially in resource-limited settings due to its low cost and effectiveness.
  4. Abacavir (ABC): Abacavir is an alternative to Tenofovir for patients who are at risk of kidney damage. However, it requires testing for the HLA-B*5701 allele, as patients with this genetic marker may experience a severe allergic reaction to the drug.

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

  1. Efavirenz (EFV): Efavirenz has been a cornerstone of HIV treatment for many years. However, it can cause neuropsychiatric side effects such as vivid dreams, anxiety, and depression in some patients.
  2. Rilpivirine (RPV): Rilpivirine is a newer NNRTI with fewer side effects than Efavirenz. It is commonly used in single-tablet regimens like Complera.

Protease Inhibitors (PIs)

  1. Atazanavir (ATV): Atazanavir is commonly used in combination with a boosting agent like Ritonavir or Cobicistat to enhance its effectiveness. It has fewer metabolic side effects compared to older PIs.
  2. Darunavir (DRV): Darunavir is often the preferred protease inhibitor for patients who have developed resistance to other drugs. It is usually taken with Ritonavir or Cobicistat as a booster.

Integrase Strand Transfer Inhibitors (INSTIs)

  1. Dolutegravir (DTG): Dolutegravir is one of the most widely used HIV medications due to its potent viral suppression, low side effect profile, and high barrier to resistance.
  2. Bictegravir (BIC): Bictegravir is found in the combination pill Biktarvy, which is a once-daily regimen. It is highly effective and well-tolerated by most patients.

Combination Therapies

  1. Truvada: A combination of Tenofovir and Emtricitabine, Truvada is used for both HIV treatment and pre-exposure prophylaxis (PrEP) to prevent infection in high-risk individuals.
  2. Biktarvy: This single-tablet regimen combines Bictegravir, Tenofovir alafenamide, and Emtricitabine. It is a popular once-daily treatment option with a low risk of side effects.
  3. Genvoya: Genvoya combines Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir alafenamide. It is taken once daily and has a lower risk of kidney and bone toxicity compared to older regimens.

Where is HIV Most Prevalent?

HIV is a global pandemic, but its prevalence varies significantly by region. Certain areas, particularly in sub-Saharan Africa, continue to bear the heaviest burden of the disease. Understanding the geographic distribution of HIV is critical for targeting prevention and treatment efforts.

High-Prevalence Regions

  1. Sub-Saharan Africa: This region has the highest rates of HIV infection in the world, accounting for approximately 70% of all people living with HIV. Countries like South Africa, Eswatini (formerly Swaziland), Lesotho, and Botswana have some of the highest HIV prevalence rates, with up to 25% of the adult population infected in some areas.
  2. Eastern Europe and Central Asia: HIV rates are rising in Eastern Europe and Central Asia, particularly among people who inject drugs. Russia and Ukraine are two of the most affected countries in this region.
  3. Caribbean: The Caribbean has the highest HIV prevalence outside of sub-Saharan Africa. Countries such as Haiti and the Dominican Republic continue to face significant challenges in addressing the epidemic, though progress has been made.

Moderate-Prevalence Regions

  1. Asia and the Pacific: Although overall HIV prevalence is lower in Asia, countries like Thailand, Myanmar, and Cambodia have concentrated epidemics, particularly among key populations such as MSM and people who inject drugs.
  2. Latin America: In Latin America, HIV is most prevalent in countries like Brazil, Mexico, and Colombia. The epidemic is concentrated among MSM, transgender individuals, and sex workers.
  3. North America and Western Europe: These regions have relatively low HIV prevalence due to widespread access to ART, prevention programs, and education. However, certain populations, such as MSM, people who inject drugs, and African and Caribbean immigrants, remain disproportionately affected.

Low-Prevalence Regions

  1. Middle East and North Africa: Although HIV prevalence is low in the Middle East and North Africa, the epidemic is growing, particularly among key populations such as MSM, people who inject drugs, and sex workers.
  2. Oceania: Countries like Australia and New Zealand have low HIV prevalence rates, but there are pockets of higher risk, particularly among MSM and Indigenous populations.

Prevention of HIV

Preventing the spread of HIV involves a combination of strategies, including behavioral interventions, biomedical approaches, and public health measures. Prevention efforts focus on reducing the risk of transmission through education, access to condoms, needle exchange programs, and antiretroviral medications.

Behavioral Interventions

  1. Safer Sex Practices: Using condoms consistently and correctly during sexual intercourse is one of the most effective ways to prevent HIV transmission. Educating people on the importance of safer sex and providing access to condoms are key prevention strategies.
  2. Limiting the Number of Sexual Partners: Reducing the number of sexual partners can lower the risk of HIV exposure. Open communication about HIV status and regular testing are also important for preventing transmission.
  3. HIV Testing and Counseling: Regular HIV testing, particularly for high-risk populations, helps ensure early diagnosis and treatment. Voluntary counseling and testing programs can provide individuals with information about their HIV status and how to prevent transmission.
  4. Avoiding Sharing Needles: For people who inject drugs, using sterile needles and avoiding needle sharing can significantly reduce the risk of HIV transmission. Needle exchange programs and safe injection sites have been shown to be effective in reducing HIV transmission among PWID.

Biomedical Interventions

  1. Pre-Exposure Prophylaxis (PrEP): PrEP is a highly effective prevention strategy for individuals at high risk of HIV infection. It involves taking a daily antiretroviral medication (such as Truvada or Descovy) to reduce the risk of contracting HIV. When taken consistently, PrEP reduces the risk of HIV from sexual transmission by more than 90% and from injection drug use by more than 70%.
  2. Post-Exposure Prophylaxis (PEP): PEP is an emergency prevention measure for people who may have been exposed to HIV. It involves taking antiretroviral medications for 28 days after potential exposure. PEP must be started within 72 hours of exposure to be effective.
  3. Treatment as Prevention (TasP): People with HIV who achieve and maintain an undetectable viral load through ART cannot transmit the virus to others. This concept, known as “undetectable = untransmittable” (U=U), is a key strategy for preventing the spread of HIV.
  4. Voluntary Medical Male Circumcision (VMMC): Studies have shown that circumcision can reduce the risk of heterosexual men acquiring HIV by approximately 60%. VMMC programs are being implemented in high-prevalence areas, particularly in sub-Saharan Africa.

Public Health Measures

  1. Education and Awareness Campaigns: Public health campaigns aimed at raising awareness about HIV transmission, testing, and prevention are crucial in reducing stigma and encouraging people to take preventive measures.
  2. Needle Exchange Programs: Needle exchange programs provide sterile needles to people who inject drugs, reducing the risk of HIV transmission through contaminated needles. These programs also offer access to HIV testing, counseling, and treatment.
  3. Harm Reduction Services for Key Populations: Programs that provide support, education, and resources for key populations, such as sex workers, MSM, and transgender individuals, can help reduce their risk of contracting HIV.
  4. Mother-to-Child Transmission Prevention (MTCT): Pregnant women living with HIV can reduce the risk of transmitting the virus to their child by taking ART during pregnancy, labor, and breastfeeding. With proper treatment, the risk of mother-to-child transmission can be reduced to less than 1%.

Related Posts:

You may also like...